Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Our work is reader-supported. Sign up to our free or paid plans here.
Oregon Psilocybin Services (OPS) has now published its second dataset for 2025, with updates summarised in our Oregon Psilocybin Services Tracker. Here, we share a summary of the main takeaways for Pα+ subscribers.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.
Topline results from the latest in our series of psychedelics investor surveys. For detailed analysis, subscribe to Pα+ today.
Dispatch: Borealis Summit Puts Compass Pathways’ Minimal Support Model Under Microscope • IV Ketamine Outperforms IN Esketamine in Retrospective Study • Reunion Neuroscience Advances RE104 While Academic Preclinical Study of Psilocybin Raises Postpartum Questions • Mindstate Design Labs Completes Phase I Study, Teases First Fixed-Dose Combination Program • New York Assembly Discusses Psilocybin • and more…
atai Wins $11.4M NIDA Grant to Develop Non-Hallucinogenic Psychedelics for OUD • Australia’s Largest Private Health Insurer Funds Psilocybin for Treatment-Resistant Depression Pilot • Osmind and Bendable Share Real-World Outcomes from 88 Psilocybin Clients • Psychedelic Pipeline Bullseye Chart Update Log • Pennsylvania Lawmakers Talk Psychedelics in Hearing on Treatment-Resistant Depression • Reunion Upsizes Series A to $133M Following Phase 2 Success • Virtual Ketamine Startup Noma Therapy to Wind Down Operations • Feilding Commission Launches to Develop UK Framework for Psychedelic-Assisted Therapy • Neurocrine’s Osavampator Prints Positive Phase 2 Results • atai and Beckley Share Positive Open-Label Two-Dose Data • and more…
MindMed’s Phase 2b LSD (MM120) for generalised anxiety disorder (GAD) study, published in JAMA earlier this month, shows promising efficacy and a favourable safety profile. Here, we speak to researchers about the trial, diving deeper into topics including the dose-response effect, the candidate’s safety profile, and non-pharmacological elements of the study, including the company’s decision not to record any of the sessions in its Phase 2b or Phase 3 studies.
Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.
The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.
It’s exclusively available to our Pα+ subscribers, with new content added regularly.
Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.
Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.
Archived versions of our Psychedelic News Feed.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing September 29, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing September 22, 2025.
This is an archived version of our Psychedelic News Feed, from January 5 – June 1, 2025
This is an archived version of our Psychedelic News Feed, from September 2 to December 29, 2024.
This is an archived version of our Psychedelic News Feed, from March 4, 2024 – September 1, 2024.
A special version of our Psychedelic News Feed to mark April 1st, 2024.
Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond
Insights and interviews delivered to your inbox. No spam, just valuable information.
